StonvexLoading…
StonvexStonvexStonvexCore line items from ESRT's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Annual 2025 2025-12-31 | Annual 2024 2024-12-31 | Annual 2023 2023-12-31 | Annual 2022 2022-12-31 |
|---|---|---|---|---|
Revenue | $766.79M | $766.75M | $738.22M | $725.68M |
Operating Income | $135.65M | $158.71M | $146.71M | $127.03M |
Net Income | $72.98M | $80.36M | $84.41M | $63.21M |
EPS (Diluted) | $0.25 | $0.28 | $0.30 | $0.22 |
Total Assets | $4.47B | $4.51B | $4.22B | $4.16B |
Total Liabilities | $2.65B | $2.73B | $2.49B | $2.48B |
Cash & Equivalents | $132.66M | $385.46M | $346.62M | $264.43M |
Free Cash Flow OCF − CapEx | $50.55M | $87.99M | $93.16M | $84.91M |
Shares Outstanding | 270.04M | 269.02M | 265.63M | 269.95M |